Algernon Pharmaceuticals Inc (AGNPF)

$0.06 +0.01 (13.33%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 54,200
Avg Vol 7,432
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 100%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and c...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 398 4175
Address:
601 West Broadway, Suite 400, Vancouver, Canada
StreetwiseReports
StreetwiseReports Jun. 24 at 10:30 PM
Grey Matters Health Inc. Advances US Alzheimer's Clinics https://ow.ly/ZxY650Zgy0N Grey Matters Health Inc. closes CA$1.25M financing to launch brain-specific PET clinics targeting the expanding Alzheimer's diagnostics market and early detection demand. $GREY.CN $AGNPF
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 24 at 4:49 PM
Alzheimer's Imaging Push Gains Fresh Funding as U.S. Clinic Plans Move Forward https://ow.ly/LHub50ZglXR Grey Matters Health Inc. ( $GREY.CN $AGNPF ) closed an expanded US$1.25 million private placement and said proceeds will support its Alzheimer's disease program and planned first U.S. brain-specific neuroimaging clinic.
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 10 at 6:40 PM
Grey Matters Health Positions for Growth in Expanding Alzheimer's Diagnostics Market https://ow.ly/In5w50Zaawh Grey Matters Health advances its Alzheimer's neuroimaging strategy with fresh financing and plans for the first U.S. brain-specific PET clinic, capitalizing on rising demand for early detection tools. $GREY.CN $AGNPF
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 9 at 10:09 PM
Alzheimer's Diagnostic Clinic Initiative Moves Forward After Financing Close https://ow.ly/wVZN50Z9H2r Grey Matters Health Inc. ( $GREY.CN $AGNPF ) closed the first CA$500,000 tranche of a financing that the company said will support its Alzheimer's disease program and planned U.S. brain-specific neuroimaging clinic.
0 · Reply
StreetwiseReports
StreetwiseReports May. 29 at 5:15 PM
New Alzheimer's Imaging Push Expands as Financing Terms Get Investor-Friendly https://ow.ly/mHpo50Z5I24 Grey Matters Health Inc. ( $GREY.CN $AGNPF ) amended warrant terms tied to its CA$1 million private placement as it advances plans for a U.S. brain-specific neuroimaging clinic focused on Alzheimer's diagnostics.
0 · Reply
StreetwiseReports
StreetwiseReports May. 22 at 3:48 PM
200 Brain PET Scans, 162 Alzheimer's Drugs: A Diagnostic Push Takes Shape https://ow.ly/i5Hs50Z3gK4 Grey Matters Health Inc. ( $GREY.CN $AGNPF ) signed an LOI tied to a minimum of 200 brain PET scans for an Alzheimer's clinical trial while expanding its NovaScan neuroimaging strategy.
0 · Reply
applemnop
applemnop May. 15 at 1:42 AM
$AGNPF when will clinics open ?
0 · Reply
levywins
levywins May. 13 at 4:10 PM
$AGNPF https://smallcappower.com/top-stories/grey-matters-health-cse-grey-targeting-a-rapidly-expanding-neuroimaging-opportunity/
0 · Reply
StreetwiseReports
StreetwiseReports Apr. 6 at 6:33 PM
Name Change, Share Consolidation, and US Clinic Strategy Signal Shift Toward Alzheimer's Diagnostics https://ow.ly/L2Zj50YEBwQ Algernon Health ( $AGN.CN $AGNPF ) plans to rebrand to Grey Matters Health Inc. while advancing its Alzheimer's diagnostic strategy and U.S. clinic rollout.
0 · Reply
StreetwiseReports
StreetwiseReports Mar. 27 at 6:11 PM
First US Brain-Only PET Clinic Targets Alzheimer's Detection as Diagnostic Demand Expands https://ow.ly/pgiM50YzTfi Algernon Health ( $AGN.CN $AGNPF ) is opening its inaugural brain PET clinic in Florida with a five-year lease and renewal option.
0 · Reply
Latest News on AGNPF
No data available.
StreetwiseReports
StreetwiseReports Jun. 24 at 10:30 PM
Grey Matters Health Inc. Advances US Alzheimer's Clinics https://ow.ly/ZxY650Zgy0N Grey Matters Health Inc. closes CA$1.25M financing to launch brain-specific PET clinics targeting the expanding Alzheimer's diagnostics market and early detection demand. $GREY.CN $AGNPF
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 24 at 4:49 PM
Alzheimer's Imaging Push Gains Fresh Funding as U.S. Clinic Plans Move Forward https://ow.ly/LHub50ZglXR Grey Matters Health Inc. ( $GREY.CN $AGNPF ) closed an expanded US$1.25 million private placement and said proceeds will support its Alzheimer's disease program and planned first U.S. brain-specific neuroimaging clinic.
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 10 at 6:40 PM
Grey Matters Health Positions for Growth in Expanding Alzheimer's Diagnostics Market https://ow.ly/In5w50Zaawh Grey Matters Health advances its Alzheimer's neuroimaging strategy with fresh financing and plans for the first U.S. brain-specific PET clinic, capitalizing on rising demand for early detection tools. $GREY.CN $AGNPF
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 9 at 10:09 PM
Alzheimer's Diagnostic Clinic Initiative Moves Forward After Financing Close https://ow.ly/wVZN50Z9H2r Grey Matters Health Inc. ( $GREY.CN $AGNPF ) closed the first CA$500,000 tranche of a financing that the company said will support its Alzheimer's disease program and planned U.S. brain-specific neuroimaging clinic.
0 · Reply
StreetwiseReports
StreetwiseReports May. 29 at 5:15 PM
New Alzheimer's Imaging Push Expands as Financing Terms Get Investor-Friendly https://ow.ly/mHpo50Z5I24 Grey Matters Health Inc. ( $GREY.CN $AGNPF ) amended warrant terms tied to its CA$1 million private placement as it advances plans for a U.S. brain-specific neuroimaging clinic focused on Alzheimer's diagnostics.
0 · Reply
StreetwiseReports
StreetwiseReports May. 22 at 3:48 PM
200 Brain PET Scans, 162 Alzheimer's Drugs: A Diagnostic Push Takes Shape https://ow.ly/i5Hs50Z3gK4 Grey Matters Health Inc. ( $GREY.CN $AGNPF ) signed an LOI tied to a minimum of 200 brain PET scans for an Alzheimer's clinical trial while expanding its NovaScan neuroimaging strategy.
0 · Reply
applemnop
applemnop May. 15 at 1:42 AM
$AGNPF when will clinics open ?
0 · Reply
levywins
levywins May. 13 at 4:10 PM
$AGNPF https://smallcappower.com/top-stories/grey-matters-health-cse-grey-targeting-a-rapidly-expanding-neuroimaging-opportunity/
0 · Reply
StreetwiseReports
StreetwiseReports Apr. 6 at 6:33 PM
Name Change, Share Consolidation, and US Clinic Strategy Signal Shift Toward Alzheimer's Diagnostics https://ow.ly/L2Zj50YEBwQ Algernon Health ( $AGN.CN $AGNPF ) plans to rebrand to Grey Matters Health Inc. while advancing its Alzheimer's diagnostic strategy and U.S. clinic rollout.
0 · Reply
StreetwiseReports
StreetwiseReports Mar. 27 at 6:11 PM
First US Brain-Only PET Clinic Targets Alzheimer's Detection as Diagnostic Demand Expands https://ow.ly/pgiM50YzTfi Algernon Health ( $AGN.CN $AGNPF ) is opening its inaugural brain PET clinic in Florida with a five-year lease and renewal option.
0 · Reply
StreetwiseReports
StreetwiseReports Mar. 26 at 4:39 PM
America's First Brain-Dedicated PET Scanning Clinics: A Turnaround Play for Chart-Savvy Investors? https://ow.ly/6g3h50YzjhR Technical Analyst Stewart Thomson explains why he thinks Algernon Health ( $AGN.CN $AGNPF ) is a Strong Speculative Buy.
0 · Reply
StreetwiseReports
StreetwiseReports Sep. 5 at 5:57 PM
Healthcare Firm Targets Alzheimer's With Technology Breakthrough https://ow.ly/pzjQ50WS8Fx Healthcare company Algernon Health rebrands and unveils plan to open brain-specific PET scanning clinics in North America to meet rising demand for Alzheimer's diagnostics. Read more to learn how this shift positions the company at the center of a growing medical need. $AGN.CN $AGNPF
0 · Reply
StreetwiseReports
StreetwiseReports Jul. 7 at 10:28 PM
Biotech Firm Adjusts Placement Terms to Fuel U.S. Expansion https://ow.ly/owWk50Wm1Mz Canadian healthcare and clinical stage drug development company Algernon Pharmaceuticals Inc. updates the pricing and warrant terms for its previously announced non-brokered private placement. Read why one technical analyst thinks the stock is ready to break out. $AGN.CN $AGNPF
0 · Reply
StreetwiseReports
StreetwiseReports May. 30 at 6:54 PM
Biotech Firm Gains Exclusive Alzheimer's Rights in U.S. and Canada https://ow.ly/qp4e50W1Ptk Algernon Pharmaceuticals Inc. secures exclusive Alzheimer's clinic rights in Canada and key U.S. cities, positioning for a high-growth breakthrough. Learn how Algernon plans to launch cutting-edge clinics featuring PET scan technology and expand into a multibillion-dollar diagnostics market $AGN.CN $AGNPF
0 · Reply
StreetwiseReports
StreetwiseReports May. 23 at 6:35 PM
Co. Poised to Begin Major New Bull Market: https://ow.ly/VjZB50VY19H Technical Analyst Clive Maund explains why he thinks Algernon Pharmaceuticals Inc. is an Immediate Strong Buy. $AGN.CN $AGNPF
0 · Reply
StreetwiseReports
StreetwiseReports May. 13 at 6:57 PM
Biotech Firm Unlocks Alzheimer's Market with U.S. Clinic Launch: https://ow.ly/sokT50VS3rp Algernon Pharmaceuticals Inc. has acquired NoBrainer Imaging, unlocking Alzheimer's PET scan clinics in Florida, Los Angeles, five select U.S. cities, and Canada. Read more to explore the growth potential. $AGN.CN $AGNPF
0 · Reply
MicsMugz
MicsMugz May. 13 at 5:11 PM
$HTOO $AGNPF
1 · Reply
MacZR
MacZR Apr. 29 at 3:59 PM
$AGNPF one post from the company every couple months if we’re lucky, lol, How do these people get to run companies.
0 · Reply
StreetwiseReports
StreetwiseReports Feb. 14 at 10:15 PM
DMT Study Set To Explore Breakthrough Potential in Stroke Recovery: https://ow.ly/apls50V0AFn Algernon Pharmaceuticals Inc. $AGN:CSE $AGNPF subsidiary Algernon NeuroScience has appointed Dr. Sndor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research.
0 · Reply
Finkleiseinhorn
Finkleiseinhorn Jan. 30 at 2:01 AM
$AGNPF what in the hell 15 percent
0 · Reply
Finkleiseinhorn
Finkleiseinhorn Jan. 28 at 2:26 AM
$AGNPF my god I have so many shares of this
0 · Reply
StreetwiseReports
StreetwiseReports Jul. 19 at 9:55 PM
Study Shows 93% Cough Suppression With Co.'s Drug: https://ow.ly/cxU050SGqTq Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. $AGN:CSE $AGNPF announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market." #pharmastocks
0 · Reply